Related references
Note: Only part of the references are listed.Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients
A. Z. Aliabadi et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics
Ahmad Awada et al.
EUROPEAN JOURNAL OF CANCER (2008)
Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness
Laurence Chan et al.
TRANSPLANTATION (2008)
Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor
Antoine Durrbach et al.
TRANSPLANTATION (2008)
Pericardial effusion coincident with sirolimus therapy: A review of Wyeth's safety database
George H. Steele et al.
TRANSPLANTATION (2008)
Reduced exposure to calcineurin inhibitors in renal transplantation
Henrik Ekberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat
Regina Vogelbacher et al.
TRANSPLANTATION (2007)
A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus
James A. Hill et al.
TRANSPLANTATION (2007)
Crossreactivity of isolated everolimus metabolites with the innofluor certican immunoassay for therapeutic drug monitoring of everolimus
Tobin Strom et al.
THERAPEUTIC DRUG MONITORING (2007)
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis
Hendrik Seeliger et al.
CANCER AND METASTASIS REVIEWS (2007)
Posttransplantation conversion to sirolimus-based immunosuppression: A single center experience
L. T. Santamaria Saber et al.
TRANSPLANTATION PROCEEDINGS (2007)
Everolimus-associated interstitial pneumonitis in a patient with a heart transplant
Sascha David et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Phase I study of everolimus in pediatric patients with refractory solid tumors
Maryam Fouladi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients
Tobin Strom et al.
THERAPEUTIC DRUG MONITORING (2007)
Targeting the mTOR signaling network in cancer
Gary G. Chiang et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms
Judith Gomez-Camarero et al.
TRANSPLANTATION (2007)
Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients
A. Sanchez Fructuoso et al.
TRANSPLANTATION PROCEEDINGS (2007)
Early Sirolimus use with cyclosporine elimination does not induce progressive proteinuria
J. C. Ruiz et al.
TRANSPLANTATION PROCEEDINGS (2007)
Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients
A. Sanchez Fructuoso et al.
TRANSPLANTATION PROCEEDINGS (2007)
Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain:: Preliminary results of the EVERODATA registry
J. C. Ruiz et al.
TRANSPLANTATION PROCEEDINGS (2007)
mTOR inhibitors:: Do they help preserve renal function?
J. Moro et al.
TRANSPLANTATION PROCEEDINGS (2007)
MTOR signalling in human cancer
J. Albanell et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2007)
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2007)
Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients
Gero Tenderich et al.
CLINICAL TRANSPLANTATION (2007)
Possible role of everolimus in improving renal function in long-term heart transplantation
R. Fiocchi et al.
TRANSPLANTATION PROCEEDINGS (2007)
Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy
M. Liu et al.
TRANSPLANTATION PROCEEDINGS (2007)
Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake
Robert Laplanche et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A
Lars Pape et al.
PEDIATRIC TRANSPLANTATION (2007)
Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation
J. W. de Fijter
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: Effect on renal function and proteinuria
J. Morales et al.
TRANSPLANTATION PROCEEDINGS (2007)
Proteinuria in transplant patients associated with sirolimus
A. F. V. Franco et al.
TRANSPLANTATION PROCEEDINGS (2007)
Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency
Nassim Kamar et al.
TRANSPLANT INTERNATIONAL (2007)
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma
T. Haritunians et al.
LEUKEMIA (2007)
Chronic allograft nephropathy score before sirolimus rescue predicts allograft function in renal transplant patients
A. Basu et al.
TRANSPLANTATION PROCEEDINGS (2007)
Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology
Hannah Valantine
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2007)
Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: A 24-month analysis
Mario Vigano et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2007)
12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients
Helio Tedesco-Silva et al.
TRANSPLANT INTERNATIONAL (2007)
Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction
R. K. Wali et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells
Kathrin Zitzmann et al.
NEUROENDOCRINOLOGY (2007)
Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus
J. M. Kovarik et al.
TRANSPLANTATION PROCEEDINGS (2006)
Everolimus drug interactions: Application of a classification system for clinical decision making
John M. Kovarik et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2006)
Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence
Atul V. Mulay et al.
TRANSPLANTATION (2006)
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12-and 36-month results
Gary Levy et al.
LIVER TRANSPLANTATION (2006)
Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients
J. M. van den Akker et al.
KIDNEY INTERNATIONAL (2006)
Conversion to everolimus in kidney transplant recipients:: A safe and simple procedure
J. C. Ruiz et al.
TRANSPLANTATION PROCEEDINGS (2006)
Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients
Paul Salm et al.
CLINICAL BIOCHEMISTRY (2006)
Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients
Martin Schweiger et al.
TRANSPLANT IMMUNOLOGY (2006)
Target of rapamycin inhibitors (Sirolimus and Everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials
Angela C. Webster et al.
TRANSPLANTATION (2006)
Recommendations for use of everolimus after heart transplantation: Results from a Latin-American Consensus Meeting
E. A. Bocchi et al.
TRANSPLANTATION PROCEEDINGS (2006)
Resolution of sirolimus-induced pneumonitis after conversion to everolimus
B. Rehm et al.
TRANSPLANTATION PROCEEDINGS (2006)
Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up
R Bestetti et al.
TRANSPLANTATION (2006)
New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation - Report from the Cardiovascular and Renal Drugs Advisory Committee, US food and Drug Administration, November 16, 2005, Rockville, Md
WR Hiatt et al.
CIRCULATION (2006)
Sirolimus-associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism
L Straathof-Galema et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria
A Saurina et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Canadian pilot study to determine safe and effective dosing of cyclosporine and everolimus in stable cardiac transplant recipients: Twelve-week interim analysis
H. Ross et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2006)
Calcineurininhibitor-free immunosuppression using Everolimus in long term heart transplant recipients - Procedures of switching protocols and side effects
M. Rothenburger et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2006)
Everolimus versus azathioprine in maintenance lung transplant recipients: An international, randomized, double-blind clinical trial
GI Snell et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Everolimus (certican) in heart transplantation: Optimizing renal function through minimizing cyclosporine exposure
H Lehmkuhl et al.
TRANSPLANTATION PROCEEDINGS (2005)
Sirolimus in cardiac transplantation: Use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity
SS Kushwaha et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2005)
Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy
JD Coombes et al.
KIDNEY INTERNATIONAL (2005)
Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state
O Thaunat et al.
TRANSPLANTATION (2005)
Improvement of renal disfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation
J Hunt et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2005)
Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: Experience of a single center
M Fernandez-Valls et al.
TRANSPLANTATION PROCEEDINGS (2005)
Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients
S Vítko et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Pharmacokinetic interaction between verapamil and everolimus in healthy subjects
JM Kovarik et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and anaplastic large cell lymphomas
F Jundt et al.
BLOOD (2005)
Everolimus versus mycophenolate mofetil in the prevention of rejection in de Novo renal transplant recipients: A 3-year randomized, multicenter, phase III study
MI Lorber et al.
TRANSPLANTATION (2005)
Rapamycin inhibits human renal epithelial cell proliferation: Effect on cyclin D3 mRNA expression and stability
N Pallet et al.
KIDNEY INTERNATIONAL (2005)
Blood concentrations of everolimus are markedly increased by ketoconazole
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data
MI Lorber et al.
CLINICAL TRANSPLANTATION (2005)
Recommendations for use of Certican® (everolimus) after heart transplantation:: Results from a German and Austrian consensus conference
M Hummel
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2005)
Effect of multiple-dose erythromycin on everolimus pharmacokinetics
JM Kovarik et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies
S Vitko et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Sirolimus-associated diffuse alveolar hemorrhage
NE Vlahakis et al.
MAYO CLINIC PROCEEDINGS (2004)
Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure
J Groetzner et al.
TRANSPLANTATION (2004)
Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation
A Azzola et al.
TRANSPLANTATION (2004)
Comparison of outcomes after delayed graft function: Sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens
RA McTaggart et al.
TRANSPLANTATION (2004)
First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation
F Trösch et al.
THORACIC AND CARDIOVASCULAR SURGEON (2004)
Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction
F Diekmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years - A randomized clinical trial
A Keogh et al.
CIRCULATION (2004)
Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus
PG Dean et al.
TRANSPLANTATION (2004)
Ischemia-reperfusion induces glomerular and tubular and activation of proinflammatory and antiapoptotic pathways: Differential modulation by rapamycin
A Loverre et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury
TF Fuller et al.
TRANSPLANTATION (2003)
Apoptosis and treatment of chronic allograft nephropathy with everolimus
J Lutz et al.
TRANSPLANTATION (2003)
Use of rapamycin slows progression of cardiac transplantation vasculopathy
D Mancini et al.
CIRCULATION (2003)
Everolimus in pediatric de novo renal transplant patients
PF Hoyer et al.
TRANSPLANTATION (2003)
Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses
M Majewski et al.
TRANSPLANTATION (2003)
Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use
KD Smith et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation
RA McTaggart et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
Effect of rifampin on apparent clearance of everolimus
JM Kovarik et al.
ANNALS OF PHARMACOTHERAPY (2002)
Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients
R Van Damme-Lombaerts et al.
PEDIATRIC TRANSPLANTATION (2002)
Effect of food on everolimus absorption: Quantification in healthy subjects and a confirmatory screening in patients with renal transplants
JM Kovarik et al.
PHARMACOTHERAPY (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: A clinically relevant pharmacokinetic interaction
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment
JM Kovarik et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
E Morelon et al.
TRANSPLANTATION (2001)
Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications
JM Kovarik et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry
G Lhoëst et al.
JOURNAL OF MASS SPECTROMETRY (2001)
Rescue therapy: A role for sirolimus in lung and heart transplant recipients
GI Snell et al.
TRANSPLANTATION PROCEEDINGS (2001)
Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression
C Schwarz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2001)
Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD
W Jacobsen et al.
TRANSPLANTATION PROCEEDINGS (2001)
Pharamacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients
GA Levy et al.
TRANSPLANTATION (2001)
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine
JM Kovarik et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD
GI Kirchner et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
The impact of immunosuppressive drugs on the analysis of T-cell activation
P Rovira et al.
CURRENT MEDICINAL CHEMISTRY (2000)
Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry
K Hallensleben et al.
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY (2000)
SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts
O Viklicky et al.
TRANSPLANTATION (2000)
Share Paper
